

Office Action of April 28, 2008 for record purposes.

DETAILED ACTION

1. The Amendment filed January 11, 2008 in response to the Office Action of October 11, 2007 is acknowledged and has been entered. Previously pending claims 6, 7 and 17 have been cancelled, claims 4, 5, and 8-10 have been amended
2. Claims 4, 5, and 8-10 are currently being examined.
3. The following rejections are being maintained:

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 4, 8, and 9 remain rejected under 35 USC 112, first paragraph for the reasons previously set forth in the Office Action of October 11, 2007, section 12-pages 13-19.

Applicants argue that with respect to the Examiner's assertion that the nucleic acid set forth in SEQ ID NO: 3 can code for a protein or polypeptide that is present in the nucleus of the animal cell, the nucleic acid set forth in SEQ ID NO: 3 can be present both in the nucleus and the cytoplasm.

Applicants argue that in order to assist the Examiner, claim 4, upon which claim 8 also depends, has been amended to define the nucleic acid recited in the claims as the nucleic acid set forth in SEQ ID NO: 3 and a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID NO: 3. As acknowledged by the Examiner in the Office Action, the present application discloses SEQ ID NO: 3. The present application discloses that the term "nucleic acid of the present invention" can include a complementary strand selected from information of the nucleic acid set forth in SEQ ID NO: 3 (page 22). As is also acknowledged by

the Examiner, it is known in the art that the phrase "complementary strands of nucleic acids" can include nucleic acids that are completely complementary to the claimed polynucleotide.

Applicants arguments have been considered, but have not been found persuasive as the claims are still drawn to fragments of SEQ ID NO: 3. Claims 4, 7 , and 9 are drawn to "A recombinant vector comprising **a purified nucleic acid coding for a** (emphasis added) protein or polypeptide . . . wherein the nucleic acid is set forth **in** (emphasis added) SEQ ID NO: 3 or is a nucleic acid that is completely complementary to the nucleic set forth **in** (emphasis added) SSEQ ID NO: 3 . . ." and a host cell transformed with the vector and a method of producing the protein. This claim construction clearly reads on fragments of SEQ ID NO: 3 as the claims are not drawn to the protein or polypeptide produced from a nucleic acid comprising SEQ ID NO: 3. The claims are not enabled to make a fragment of SEQ ID NO: 3 that is present in the nucleus and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene or a gene product thereof, given that the specification has not identified the regions of the encoded polypeptide that are required for these functions and given the unpredictability of protein biochemistry and predicting function from structure previously set forth. Thus undue experimentation would be required to identify fragments that encode a protein with the claimed functions.

Applicant's arguments have not been found persuasive and the rejection is maintained.

5. Claims 4, 8 and 9 remain rejected under 35 USC 112, first paragraph for the reasons previously set forth in the Office Action of October 11, 2007, section, 13, pages 19-24.

Applicants argue that in order to assist the Examiner, claim 4, upon which claim 8 also depends, has been amended to define the nucleic acid recited in the claims as the nucleic acid set

forth in SEQ ID NO: 3 and a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID NO: 3. As acknowledged by the Examiner in the Office Action, the present application discloses SEQ ID NO: 3. As is also acknowledged by the Examiner, it is known in the art that the phrase "complementary strands of nucleic acids" can include nucleic acids that are completely complementary to the claimed polynucleotide.

Applicants arguments have been considered, but have not been found persuasive as the claims are still drawn to fragments of SEQ ID NO: 3. Claims 4, 8 , and 9 are drawn to "A recombinant vector comprising **a purified nucleic acid coding for a** (emphasis added) protein or polypeptide . . . wherein the nucleic acid is set forth **in** (emphasis added) SEQ ID NO: 3 or is a nucleic acid that is completely complementary to the nucleic set forth **in** (emphasis added) SSEQ ID NO: 3 . . ." and a host cell transformed with the vector and a method of producing the protein. This claim construction clearly reads on fragments of SEQ ID NO: 3 as the claims are not drawn to the protein or polypeptide produced from a nucleic acid comprising SEQ ID NO: 3. Thus, the claims are not enabled to make a fragment of SEQ ID NO: 3 that is present in the nucleus and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene or a gene product thereof given that the specification has not identify the regions of the encoded polypeptide that are required for these functions and undue experimentation would be required to identify fragments that encode a protein with the claimed functions. The level of skill and knowledge in the art is such that one of ordinary skill would not be able to identify without further testing which of these fragment of SEQ ID NO: 3 can code for a protein have the ability to be present in the nucleus and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene or a gene product

thereof. Thus one of skill in the art would not recognize that Applicants were in possession of the claimed genus.

Applicant's arguments have not been found persuasive and the rejection is maintained.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

6. Claims 8-10 remain rejected and claims 4 and 5 are rejected under 35 U.S.C. 102(a) as being anticipated by Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS) for the reasons forth in the Office Action of October 11, 2007, section, 15, pages 25-27.

Applicants argue that three of the authors listed in Chano et al., Chano, Ikegawa, and Okabe, are the also the inventors of the present application. The remaining three authors listed in Chano et al., Kontani, Baldini, and Saeki, were working under the direction of the present inventors and their contributions were not of an inventive nature. Applicants submit herewith a Declaration under 37 C.F.R. § 1.132 to further establish that the authors of Chano et al. are the inventors of the present application. As such, Applicants respectfully submit that Chano et al. does not qualify as an invention known or used by "others" within the meaning of 35 U.S.C. §102(a).

The Declaration under 37 CFR 1.132 filed January 11, 2008 is insufficient to overcome the rejection of claims 4, 5 and 8-10 based upon Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS) as set forth in the last Office action because: The Declarants state in section 1:

We, Tokuhiro Chano, Shiro Ikegawa, and Hidetoshi Okabe, do declare and state as follows: **We are three of the six named inventors** (emphasis added) of the present application identified above.

Given the statement that “We are three of the six named inventors” and the identity of the other three inventors has not been made known to the Office nor have six inventors signed the Declaration, the Declaration under 37 CFR 1.132 is not an unequivocal statement from the Applicant regarding the subject matter disclosed in the article and has not properly executed, see MPEP 716.10 and CFR 1.63. Thus, the Declaration under 37 CFR 1.132 filed January 11, 2008 is insufficient to overcome the rejection.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. Claim 10 remains rejected under 35 U.S.C. 103(a) as being unpatentable over AB059622 (October 11, 2001), in view of Mensink et al (British J. Haematol. (August 1998) 102:768-774) and further in view of Buck et al (Biotechniques (1999) 27(3):528-536) for the reasons forth in the Office Action of October 11, 2007, section, 16, pages 28-30.

Applicants argue that as acknowledged by the Examiner, AB059622 does not teach the particular primers of SEQ ID Nos: 19 and 20. Mensink et al. and Buck et al. also do not, alone or in combination, teach or suggest SEQ ID Nos: 19 and 20. With reference to the Examiner's

assertion that published sequences may be analyzed by commercially available software for primer selection in many cases, one can use the "Primer 3 website" (primer3.sourceforge.net) for this purpose rather than the commercially available software taught in Mensink et al. Simply by knowing the nucleotide sequence information, one can use the "Primer 3 website" to analyze primer design with general versatility. However, only after using the designed primer, can one obtain useful information on whether or not it is applicable to an experiment or clinical. Thus, one cannot determine if a nucleotide sequence is useful, simply because the sequence is known. Accordingly, one of ordinary skill in the art would not be able to arrive at the particular primers of SEQ ID NOs: 19 and 20, simply because of the disclosure of AB059622.

Applicants arguments have been considered, but have not been found persuasive because of the availability in the art of primer design programs in the art at the time the invention was made and the teaching of Buck that every single primer tested of the 164 primers tested functioned as expected, one of skill in the art would have a reasonable expectation of success given that sequence was known in the art at the time the invention was made.

Applicant's arguments have not been found persuasive and the rejection is maintained.

New Grounds of Rejection

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

8. Claims 4, 5, and 8 are rejected under 35 U.S.C. 102(b) as being anticipated by

Nagase et al. (DNA Research, 1996, 3:321-329) as evidenced by Nomura et al. (DNA Research,

1994: 1: 27-35), Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS) and Appendix 1.

The claims are drawn to:

4. A recombinant vector comprising a purified nucleic acid coding for a protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB 1 gene) or a gene product thereof the polypeptide or protein according to claim 1, or a complementary strand thereof, wherein the nucleic acid is set forth in SEQ ID No: 3 or is a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3.

5. A recombinant vector comprising a nucleic acid hybridizing under stringent conditions with the a purified nucleic acid set forth in SEQ ID No: 3 or a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3 according to claim 3 or the complementary strand thereof; wherein the stringent conditions comprise a condition under which a positive hybridization signal is still observed even after heating at 42 °C in a solution of 6 x SSC, 0.5% SDS and 50% formamide, and washing at 68 °C in a solution of 0.1 x SSC and 0.5% SDS.

8. A transformant that was transformed with the recombinant vector according to claim 4.

Nagase et al. teach the cloning of the cDNA KIAA0203, which 99.3% identical to SEQ ID NO: 3 and codes for a protein identical to RB1CC1, see Table 1 of Nagase et al. and Appendix 1. Nagase et al. used the methods Nomura et al. for cloning the cDNA, see Materials and Methods. and reference 1 of Nagase et al. Nomura et al. teach that cDNA were cloned and

placed into the pBluescript SK+ cDNA vector and used to make cDNA libraries that were grown in colonies of cells, see p. 28, 1st col., of Nomura et al.

Chano et al. teach that RB1CC1 can induce the expression of the RB1 gene, see Abstract, Fig. 2 and Fig.4.

Although the reference does not specifically state that KIAA0203 codes for a protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and /or a function that can induce expression of retinoblastoma gene (RB1 gene) or a gene product thereof, given the teaching of Chano et al. The claimed product appears to be the same as the prior art product, absent a showing of unobvious differences. The office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product is different from those taught by the prior art and to establish patentable differences. See *In re Best* 562F.2d 1252, 195 USPQ 430 (CCPA).

Claim Rejections - 35 USC § 103

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claims 4, 5, 8, and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over AB059622 (October 11, 2001) as evidenced by Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS), in view of US Patent No. 4,889,806 (Dec. 1989) and Sambrook et al (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor, 1989, pp.16.3-4).

The claims are drawn to:

4. A recombinant vector comprising a purified nucleic acid coding for a protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB 1 gene) or a gene product thereof the polypeptide or protein according to claim 1, or a complementary strand thereof, wherein the nucleic acid is set forth in SEQ ID No: 3 or is a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3.

5. A recombinant vector comprising a nucleic acid hybridizing under stringent conditions with the a purified nucleic acid set forth in SEQ ID No: 3 or a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3 according to claim 3 or the complementary strand thereof; wherein the stringent conditions comprise a condition

under which a positive hybridization signal is still observed even after heating at 42 °C in a solution of 6 x SSC, 0.5% SDS and 50% formamide, and washing at 68 °C in a solution of 0.1 x SSC and 0.5% SDS.

8. A transformant that was transformed with the recombinant vector according to claim 4.

9. A method for producing a protein or polypeptide which is present in the nucleus of a human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB 1 gene) or a gene product thereof or a complementary strand thereof, wherein the nucleic acid is set forth in SEQ ID NO" 3 the polypeptide or protein according to claim 1 , comprising a step of culturing the transformant according to claim 8 with the recombinant vector containing nucleic acid coding for the polypeptide or protein.

AB059622 teaches as previously set forth in the Office Action of October 11, 2007, section 14, pages 24-25, but does not teach a recombinant vector comprising SEQ ID NO: 3, a transformant transformed with the recombinant vector, or a method for producing protein using the recombinant vector.

US Patent No. 4,889,806 teach that with the advent of recombinant DNA and molecular cloning technology it is now conventional to transfer genetic information into plasmids or vectors constructed in vitro and then transferred into host cells and clonally propagated (col. 1, lines 18-24).

Sambrook et al teach that cloned genes are conventionally expressed using expression vectors and that expression of cloned proteins have been used to: (1) confirm the identity of a cloned gene by using immunological or functional assays to detect the encoded protein; (2)

produce large amounts of proteins of biological interest that are normally available in only limited quantities from natural sources; (3) to study the biosynthesis and intracellular transport of proteins following their expression in various cell types; and (4) to elucidate structure-function relationships by analyzing the properties of normal and mutant proteins (para bridging pages 16.3 and 16.4).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to make a recombinant vector with the nucleic acid sequence of AB059622, transform the vector into a host cell and produce a protein with the methods of Sambrook et al and US Patent No. 4,889,806 because US Patent No. 4,889,806 specifically teaches that it is conventional to transfer genetic materials into plasmids or vectors and then transfer the plasmids or vectors into host cells and clonally propagate the genetic material and because Sambrook et al teach that cloned genes are conventionally expressed using expression vectors.

One of ordinary skill in the art at the time the invention was made would have been motivated to make a recombinant vector with the nucleic acid sequence of AB059622 with the methods of Sambrook et al and US Patent No. 4,889,806 because Sambrook et al specifically teach that expressed cloned proteins are used to: (1) confirm the identity of a cloned gene by using immunological or functional assays to detect the encoded protein; (2) produce large amounts of proteins of biological interest that are normally available in only limited quantities from natural sources; (3) to study the biosynthesis and intracellular transport of proteins following their expression in various cell types; and (4) to elucidate structure-function relationships by analyzing the properties of normal and mutant proteins. Given the conventional nature of the methods, one of skill in the art would have had a reasonable expectation of success.

Priority

10. Applicants state that at page 2, item 6, of the Office Action, the Examiner has acknowledged receipt of papers submitted under 35 U.S.C. §119(a)-(d), which papers have been placed of record in the file. The Examiner recognizes a priority date of January 30, 2003. The Examiner indicates that because the priority of the instantly claimed invention is based on Japanese Application Nos. 2002-161400 and 2002-214978, and translations have not been provided, the Examiner is unable to recognize an earlier priority date. The Examiner suggests that Applicants submit a translation of the priority documents and to point to page and line where support can be found establishing an earlier priority date.

Applicants argue that English translations are not required for claiming priority. According to MPEP § 201.15, the actual merits of an applicant's claim of priority is considered by the Examiner only when a reference is found with an effective date between the date of the foreign filing and the date of filing in the United States. None of the publication dates of the references cited by the Examiner appears to fall within this range. As such, the priority dates of the Japanese applications should be recognized.

Applicants' arguments have been considered and the conditions for foreign priority Japanese Application Nos. 2002-161400 and 2002-214978 have been met.

11. All other objections and rejections recited in Office Action of October 11, 2007 are withdrawn.

12. No claims allowed.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter J. Reddig whose telephone number is (571) 272-9031.

The examiner can normally be reached on M-F 8:30 a.m.-5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Peter J Reddig/

Examiner, Art Unit 1642

/P. J. R./

/Karen A Canella/

Primary Examiner, Art Unit 1643

Appendix 1

D86958
LOCUS D86958 6614 bp mRNA linear PRI 15-JAN-2004
DEFINITION Homo sapiens mRNA for KIAA0203 gene, partial cds.
ACCESSION D86958
VERSION D86958.1 GI:1503989
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;

Art Unit: 1642

REFERENCE 1
 AUTHORS Nagase, T., Seki, N., Ishikawa, K., Ohira, M., Kawarabayasi, Y., Ohara, O., Tanaka, A., Kotani, H., Miyajima, N. and Nomura, N.
 TITLE Prediction of the coding sequences of unidentified human genes. VI. The coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of cDNA clones from cell line KG-1 and brain
 JOURNAL DNA Res. 3 (5), 321-329 (1996)
 PUBMED 9039502
 REFERENCE 2 (bases 1 to 6614)
 AUTHORS Ohara, O., Nagase, T., Kikuno, R. and Nomura, N.
 TITLE Direct Submission
 JOURNAL Submitted (02-AUG-1996) Osamu Ohara, Kazusa DNA Research Institute, 1532-3, Yana, Kisarazu, Chiba 292-0812, Japan
 (E-mail: cdnainfo@kazusa.or.jp, Tel:+81-438-52-3913)
 FEATURES source
 source Location/Qualifiers
 1. .6614
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /chromosome="8"
 /sex="male"
 /cell_line="KG-1"
 /cell_type="myeloblast"
 <1. .6614
 /gene="KIAA0203"
 gene
 5 'UTR 1. .515
 /gene="KIAA0203"
 <510. .5291
 /gene="KIAA0203"
 CDS /note="Start codon is not identified
 similar to mouse CC1."
 /citation=[1]
 /codon_start=1
 /protein_id="BAA13194.2"
 /db_xref="GI:40788906"
 /translation="IIMKLYFVLNTGTTFDTETLVQTVADLKHAIQSKYKIAIQH
 QVLVVNGGECMAADRRVCTYSAGTDNPIFLFNKEMILCDRPPAIPKTTFSTENDMEI
 KVEESLMPAVFHTVASRTQALEMYEVAKKLCSCFCEGLVHDEHLQHQGWAAIMANLE
 DCSNSYQKLLFKFESIYSNYLQSIEDIKLKLTHLGTAVSVMAKIPLLECLTRHSYREC
 LGRLDSLPEHEDSEKAETKRSTELVLSPDMPRTTNESSLTSFPKSVEHVSPTADAES
 GKEIRESCQSTVHQDDETTIDTKDGLPFFNVSLLDWINVQDRPNDVESLVRKCFDSM
 SRLDPRIIRPFIAECRQTIAKLDNQNMKAIKGLEDRLYALDQMIASCGRGLVNEQKELA
 QGFLANQKRAENLKDASVLPDLCLSHANQLMIMLQNHHRKLLDIKQKCTTAKQELANNL
 HVRLKWCCFVMLHADQDGKEKLQALLRLVIELLERVKIVEALSTVQPQMYCLAVVEVRR
 KMFHKHYREWAGALVKGKRLYEAEKSKRESFGKFLRKSFLRNRLFRGLDSWPPSFCT
 QKPRKFDCELPDISLKDQFLQSFCESEVQPFLRVPLLCDFEPLHQHVLALHNLVKA
 QSLDEMSQTITDLSSEQKASVQSTSQPSASSPRMESTAGTTTSPRTPPPLTVQDPL
 CPAVCPLELSPDSIDAHTFDFETIPHVNIEQTIHQVSLDDSLAESPESDFMSAVNE
 FVIEENLSSPNPISDPQSPEMMVEIYSSVINAIDSRRMQDTNVCGKEFGDHTSLNV
 QLERCRVVAQDSHFSIQTIKEDLCHFRFTVQKEQCDFNSLKCATAVEIRNIIIEKVKCS
 LEITLKEHKQKELLSLKNYEYEGKLDGLIKETEENENKIKLKGEVLQNLQNKDNE
 FALVKHEKEAVICLQNEKDQKLLEMENIMHSQNCEIKELKQSREIVLEDLKKLHVEND
 EKLQLLRAELQSLRQSHLKELEDTLQVRHIQEFEKVMTDHRSLEELKKENQOIINQI
 QESHAEIIQEKQIQLQELKLKVSDLSDTRCKLEVELALKEAETDEIKILLEESRAQQK
 ETLKSLLEQETENLRTIESKLNQKIQDNNENYQVGLAELRTLMTIEKDQCISELISRH
 EEEESNLKAEALNKVTSIHNQAFEIEKNLKEQIIIELQSKLDSELSALERQKDEKITQQE
 EKYEAIIIQNLEKDRQKLVSSQEQDREQLIQKLNCEKDEAIQTALKFKEFVVEKEL
 LEKVKHLENQIAKSPAIDSTRGDSSSLVAELQEKAKFLEQLEEQEKRKNEEMQ
 NVRTSLIAEQQTNFNTVLTREKMRKENIINDLSDKLSTMQQQERDKDLIESLSEDRA
 RLLEEKKKLEEEVSKLRSSSFVPSPVVATAPELYGACAPELPGESDRSAVETADEGRV
 DSAMETSMSVQENIHMSEEKQRIIMLLERTLQLKEEENKRLNQRLMSQSMSVVSSRH
 SEKIAIRDFQVGDIVLIIILDERHDNYVLFTVSPPLYFLHSESLPALDLKPAGASRRP
 WVLGKVMKEYCQAKKAQNRFKVPLGTFYRVKAVSWNKV"
 3 'UTR 5292. .6614
 /gene="KIAA0203"
 ORIGIN

Art Unit: 1642

Query Match 99.3%; Score 6587; DB 5; Length 6614;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 6609; Conservative 0; Mismatches 5; Indels 9; Gaps 1;

Qy 10 AACAAACCAAGCCGCGCGGTGTCGCCGCCCCCTGCCGAGCCCTCGGCCTGCAGAACAT 69
 |||||||
 Db 1 AACAAACCAAGCCGCGCGGTGTCGCCGCCCCCTGCCGAGCCCTCGGCCTGCAGAACAT 60

Qy 70 CCCCCAGTCGCCCTGGGCCCTCGGCCTCTGACAGGCCGCCGCTCTGTCCCCCGCCCCA 129
 |||||||
 Db 61 CCCCCAGTCGCCCTGGGCCCTCGGCCTCTGACAGGCCGCCGCTCTGTCCCCCGCCCCA 120

Qy 130 GACCCAGAGCCGAGGGCCTGCTCGGTCTTGTCGCCGGACCCCTCCCTGCCCTCTA 189
 |||||||
 Db 121 GACCCAGAGCCGAGGGCCTGCTCGGTCTTGTCGCCGGACCCCTCCCTGCCCTCTA 180

Qy 190 GAGTTGGGCCGCGGGCGGGCGCCGGGACGCCGGGTTGTGTCGGCTTACCGGT 249
 |||||||
 Db 181 GAGTTGGGCCGCGGGCGGGCGCCGGGACGCCGGGTTGTGTCGGCTTACCGGT 240

Qy 250 GCCGAATGGCGGTTGGTAACCGCTGCCGAGGACTAGGCCGGCGGAAGATGGTGGCGG 309
 |||||||
 Db 241 GCCGAATGGCGGTTGGTAACCGCTGCCGAGGACTAGGCCGGCGGAAGATGGTGGCGG 300

Qy 310 GGGTCGCTGGCTCTGCTGCCGCCGGCGAAGGAGGAGGCGTTGCCGGTTCTGAGTT 369
 |||||||
 Db 301 GGGTCGCTGGCTCTGCTGCCGCCGGCGAAGGAGGAGGCGTTGCCGGTTCTGAGTT 360

Qy 370 TAACCAGTAATGCCATTCACTGCAATCTCAAGCAAACATAAGCCAGTTTAAT 429
 |||||||
 Db 361 TAACCAGTAATGCCATTCACTGCAATCTCAAGCAAACATAAGCCAGTTTAAT 420

Qy 430 CTACTTTAAGAAAAGTGGTAGTCCTTACAGTCGCTGACGTAACGTATCAGAGGG 489
 |||||||
 Db 421 CTACTTTAAGAAAAGTGGTAGTCCTTACAGTCGCTGACGTAACGTATCAGAGGG 480

Qy 490 TGAGGTATAAGCTCACAGAAATCAGATAAATCATCATGAAGTTATATGTATTCTGGTTA 549
 |||||||
 Db 481 TGAGGTATAAGCTCACAGAAATCAGATAAATCATCATGAAGTTATATGTATTCTGGTTA 540

Qy 550 ACACGGAACTACTCTAACATTGACACTGAACCTACAGTGCAAACTGTGGCAGACCTTA 609
 |||||||
 Db 541 ACACGGAACTACTCTAACATTGACACTGAACCTACAGTGCAAACTGTGGCAGACCTTA 600

Qy 610 AGCATGCCATTCAAAGCAAATACAAGATTGCTATTCAACACCAAGGTGCTGGTGGTCAATG 669
 |||||||
 Db 601 AGCATGCCATTCAAAGCAAATACAAGATTGCTATTCAACACCAAGGTGCTGGTGGTCAATG 660

Qy 670 GAGGAGAATGCATGGCTGCAGATCGAAGAGTGTACCTACAGTGCTGGACGGATACAA 729
 |||||||
 Db 661 GAGGAGAATGCATGGCTGCAGATCGAAGAGTGTACCTACAGTGCTGGACGGATACAA 720

Qy 730 ATCCAATTTCCTTTAACAAAGAAATGATCTTATGCATCGTCCACCTGCTATTCTCTA 789
 |||||||
 Db 721 ATCCAATTTCCTTTAACAAAGAAATGATCTTATGTATCGTCCACCTGCTATTCTCTA 780

Qy 790 AAACTACCTTCGACAGAAAATGACATGGAAATAAAAGTTGAAGAATCTCTATGATGC 849
 |||||||
 Db 781 AAACTACCTTCGACAGAAAATGACATGGAAATAAAAGTTGAAGAATCTCTATGATGC 840

Qy 850 CTGCAGTTTCATCACTGTTGCTCAAGGACACAGCTGCTGCAATTGGAAATGTATGAAGTTG 909
 |||||||
 Db 841 CTGCAGTTTCATCACTGTTGCTCAAGGACACAGCTGCTGCAATTGGAAATGTATGAAGTTG 900

Qy 910 CCAAGAAAATTGTTCTTTGTGAAGGTGTCAGATGATGAACATCTAACACCAAG 969
 |||||||

Art Unit: 1642

Db	901	CCAAGAAACTTGTCTTTGTGAAGGTCTGTACATGATGAACATCTCAACACCAAG	960
Qy	970	GCTGGCTGCAATCATGGCCAACCTGGAGGACTGTTCAAATTCAACAAAAGCTACTTT	1029
Db	961	GCTGGCTGCAATCATGGCCAACCTGGAGGACTGTTCAAATTCAACAAAAGCTACTTT	1020
Qy	1030	TCAAGTTGAAAGTATTCAAAATTATCTGCAGTCATAGAACATCAAGTTAAAC	1089
Db	1021	TCAAGTTGAAAGTATTCAAAATTATCTGCAGTCATAGAACATCAAGTTAAAC	1080
Qy	1090	TTACTCATTAGAACACTGCAGTTCAATGCCAAGATCCACTGTTGGAGTCCTAA	1149
Db	1081	TTACTCATTAGAACACTGCAGTTCAATGCCAAGATCCACTGTTGGAGTCCTAA	1140
Qy	1150	CCAGACATAGTTACAGAGAATGTTGGGAAGACTGGATTCTTACCTGAACATGAAGACT	1209
Db	1141	CCAGACATAGTTACAGAGAATGTTGGGAAGACTGGATTCTTACCTGAACATGAAGACT	1200
Qy	1210	CAGAAAAAGCTGAGACGAAAAGATCCACTGAACACTGGTGCCTCTCCTGATATGCCTAGAA	1269
Db	1201	CAGAAAAAGCTGAGACGAAAAGATCCACTGAACACTGGTGCCTCTCCTGATATGCCTAGAA	1260
Qy	1270	CAACTAACGAATCTTGTAAACCTCATTCAGTCAGTGGAACATGTGTCCCCAGATA	1329
Db	1261	CAACTAACGAATCTTGTAAACCTCATTCAGTCAGTGGAACATGTGTCCCCAGATA	1320
Qy	1330	CCGCAGATGCTGAAAGTGGCAAAGAAATTAGGAATCTGTCAAAGTACTGTTCATCAGC	1389
Db	1321	CCGCAGATGCTGAAAGTGGCAAAGAAATTAGGAATCTGTCAAAGTACTGTTCATCAGC	1380
Qy	1390	AAGATGAAACTACGATTGACACTAAAGATGGTATCTGCCCTTTTAATGTCCTTGT	1449
Db	1381	AAGATGAAACTACGATTGACACTAAAGATGGTATCTGCCCTTTTAATGTCCTTGT	1440
Qy	1450	TAGACTGGATAATGTTCAAGATAGACCTAATGATGTGGATCTTGGTCAGGAAGTGCT	1509
Db	1441	TAGACTGGATAATGTTCAAGATAGACCTAATGATGTGGATCTTGGTCAGGAAGTGCT	1500
Qy	1510	TTGATTCTATGAGCAGGCTTGATCCAAGGATTATCGACCATTAGCAGAACGCCGTC	1569
Db	1501	TTGATTCTATGAGCAGGCTTGATCCAAGGATTATCGACCATTAGCAGAACGCCGTC	1560
Qy	1570	AAACTATTGCCAAACTTGATAATCAGAATATGAAAGCCATTAAAGGACTTGAAGATCGGC	1629
Db	1561	AAACTATTGCCAAACTTGATAATCAGAATATGAAAGCCATTAAAGGACTTGAAGATCGGC	1620
Qy	1630	TCTACGCCCTGGACCAGATGATTGCTAGCTGTGGCGACTGGTGAATGAACAGAAAGAGC	1689
Db	1621	TCTACGCCCTGGACCAGATGATTGCTAGCTGTGGCGACTGGTGAATGAACAGAAAGAGC	1680
Qy	1690	TTGCTCAGGGATTTAGCTAATCAGAAGAGAGCTGAAAACCTAAAGGATGCATCTGTAT	1749
Db	1681	TTGCTCAGGGATTTAGCTAATCAGAAGAGAGCTGAAAACCTAAAGGATGCATCTGTAT	1740
Qy	1750	TACCTGATTATGCCCTGAGTCACGCAAATCAGTTGATGATTATGTTGCAAAATCATAGAA	1809
Db	1741	TACCTGATTATGCCCTGAGTCACGCAAATCAGTTGATGATTATGTTGCAAAATCATAGAA	1800
Qy	1810	AACTGTAGATATTAAGCAGAAAGTGTACCACTGCCAACACAAGAACTAGCAAATAACCTAC	1869
Db	1801	AACTGTAGATATTAAGCAGAAAGTGTACCACTGCCAACACAAGAACTAGCAAATAACCTAC	1860
Qy	1870	ATGTCAGACTGAAGTGGTGTGCTTGTAAATGCTCATGCTGATCAAGATGGAGAGAAGT	1929
Db	1861	ATGTCAGACTGAAGTGGTGTGCTTGTAAATGCTCATGCTGATCAAGATGGAGAGAAGT	1920
Qy	1930	TACAAGCTTGCTCCGCCTCGTAATAGAGCTGTTAGAAAGAGTCAAAATTGTTGAAGCTC	1989

Art Unit: 1642

Db	1921	TACAAGCTTGCTCCGCCTCGTAATAGAGCTGTTAGAAAGAGTCAAAATTGTTGAAGCTC	1980
Qy	1990	TTAGTACAGTTCCTCAGATGACTGCTTAGCTGTTGAGGTTGTAAGAAGAAAAATGT	2049
Db	1981	TTAGTACAGTTCCTCAGATGACTGCTTAGCTGTTGAGGTTGTAAGAAGAAAAATGT	2040
Qy	2050	TCATAAAACACTACAGGGAGTGGCTGGTGCTTAGTCAAAGATGGAAAGAGATTATATG	2109
Db	2041	TCATAAAACACTACAGGGAGTGGCTGGTGCTTAGTCAAAGATGGAAAGAGATTATATG	2100
Qy	2110	AAGCAGAAAAATCAAAAAGGAATCCTTGGGAAATTATTAGGAAGTCTTTTAAGAA	2169
Db	2101	AAGCAGAAAAATCAAAAAGGAATCCTTGGGAAATTATTAGGAAGTCTTTTAAGAA	2160
Qy	2170	ATCGTCTGTTAGGGACTGGACTCCTGGCCCCCTCCTTGTACTCAAAAGCCTCGAA	2229
Db	2161	ATCGTCTGTTAGGGACTGGACTCCTGGCCCCCTCCTTGTACTCAAAAGCCTCGAA	2220
Qy	2230	AGTTGACTGTGAACCTCCAGATATTCATTAAAGATTACAGTTCTGCAATCATT	2289
Db	2221	AGTTGACTGTGAACCTCCAGATATTCATTAAAGATTACAGTTCTGCAATCATT	2280
Qy	2290	GTCCTTCGGAAGTTCCAGCCATTCCAGGGTCCCTACTTGTGACTTGAACCTCTAC	2349
Db	2281	GTCCTTCGGAAGTTCCAGCCATTCCAGGGTCCCTACTTGTGACTTGAACCTCTAC	2340
Qy	2350	ACCAGCATGTACTTGCTCTACATAATTGGTAAAGCAGCACAAAGTTGGATGAAATGT	2409
Db	2341	ACCAGCATGTACTTGCTCTACATAATTGGTAAAGCAGCACAAAGTTGGATGAAATGT	2400
Qy	2410	CACAGACCATTACAGATCTACTGAGTGAACAAAAGGCATCTGTGAGCCAGACATCCCCAC	2469
Db	2401	CACAGACCATTACAGATCTACTGAGTGAACAAAAGGCATCTGTGAGTCAGACATCCCCAC	2460
Qy	2470	AGTCTGCTTCTCACCAAGGATGAAAGTACAGCAGGAATTACAACACTACCTCACCGA	2529
Db	2461	AGTCTGCTTCTCACCAAGGATGAAAGTACAGCAGGAATTACAACACTACCTCACCGA	2520
Qy	2530	GAACCTCCACCACACTGACTGTTCAAGGATCCCTATGTCCTGCAGTTGTCCTTAGAAG	2589
Db	2521	GAACCTCCACCACACTGACTGTTCAAGGATGAAAGTACAGCAGGAATTACAACACTACCTCACCGA	2580
Qy	2590	AATTATCTCCAGATAGTATTGATGCACATACGTTGATTGAAACTATTCCCCATCCAA	2649
Db	2581	AATTATCTCCAGATAGTATTGATGCACATACGTTGATTGAAACTATTCCCCATCCAA	2640
Qy	2650	ACATAGAACAGACTATTCCACCAAGTTCTTAGCTGAGTTGATTCACTAGCAGAAAGCTCG	2709
Db	2641	ACATAGAACAGACTATTCCACCAAGTTCTTAGCTGAGTTGATTCACTAGCAGAAAGCTCG	2700
Qy	2710	AATCAGATTATGCTGTGAATGAGTTGTAATAGAAGAAAATTGTCGTCTCTA	2769
Db	2701	AATCAGATTATGCTGTGAATGAGTTGTAATAGAAGAAAATTGTCGTCTCTA	2760
Qy	2770	ATCCTATAAGTGTACACAAAGCCCAGAAATGATGGTGAATCACTTATTCACTAGTTA	2829
Db	2761	ATCCTATAAGTGTACACAAAGCCCAGAAATGATGGTGAATCACTTATTCACTAGTTA	2820
Qy	2830	TCAATGCGATAGACAGTAGACGAATGCAGGATAACAAATGTATGTTAGGAGGATTG	2889
Db	2821	TCAATGCGATAGACAGTAGACGAATGCAGGATAACAAATGTATGTTAGGAGGATTG	2880
Qy	2890	GAGATCATACTCTGAAATGTCAGTTGGAAAGATGTAGAGTTGTTGCCAAGACTCTC	2949
Db	2881	GAGATCATACTCTGAAATGTCAGTTGGAAAGATGTAGAGTTGTTGCCAAGACTCTC	2940

Art Unit: 1642

Qy	2950	ACTTCAGTATAAACCATTAAGGAAGACCTTGCACTTAGAACATTGTACAAAAAG	3009
Db	2941	ACTTCAGTATAAACCATTAAGGAAGACCTTGCACTTAGAACATTGTACAAAAAG	3000
Qy	3010	AACAGTGTGACTTCTCAAATTCAATTAAAGTACAGCAGTAGAAATAAGAAACATTATTG	3069
Db	3001	AACAGTGTGACTTCTCAAATTCAATTAAAGTACAGCAGTAGAAATAAGAAACATTATTG	3060
Qy	3070	AAAAAGTAAAATGTTCTGGAAATAACACTAAAAGAAAAACATCAAAAAGAACTACTGT	3129
Db	3061	AAAAAGTAAAATGTTCTGGAAATAACACTAAAAGAAAAACATCAAAAAGAACTACTGT	3120
Qy	3130	CTTTAAAAATGAATATGAAGGAAACTTGACGGACTAATAAAGGAAACTGAAGAGAATG	3189
Db	3121	CTTTAAAAATGAATATGAAGGAAACTTGACGGACTAATAAAGGAAACTGAAGAGAATG	3180
Qy	3190	AAAACAAAATTAAAAATTGAAGGGAGAGTTAGTATGCCTGAGGAGTTTACAAAATA	3249
Db	3181	AAAACAAAATTAAAAATTGAAGGGAGAGTTAGTATGCCTGAGGAGTTTACAAAATA	3240
Qy	3250	AAGATAATGAATTGGTTAACATGAAAAAGCTGTAATCTGCCTGCAGAATG	3309
Db	3241	AAGATAATGAATTGGTTAACATGAAAAAGCTGTAATCTGCCTGCAGAATG	3300
Qy	3310	AAAAGGATCAGAAGTTAGAGATGGAAAATAATGCACTCTCAAAATTGTGAAATTA	3369
Db	3301	AAAAGGATCAGAAGTTAGAGATGGAAAATAATGCACTCTCAAAATTGTGAAATTA	3360
Qy	3370	AAGAACTGAAGCAGTCACGAGAAATAGTGTAGAGACTTAAAGCTCCATGTTGAAA	3429
Db	3361	AAGAACTGAAGCAGTCACGAGAAATAGTGTAGAGACTTAAAGCTCCATGTTGAAA	3420
Qy	3430	ATGATGAGAAGTTACAGTTATTGGGGCAGAACCTCAGTCCTGGAGCAAAGTCATCTAA	3489
Db	3421	ATGATGAGAAGTTACAGTTATTGGGGCAGAACCTCAGTCCTGGAGCAAAGTCATCTAA	3480
Qy	3490	AGGAATTAGAGGACACACTTCAGGTTAGGCACATACAAGAGTTGAGAAGGTTATGACAG	3549
Db	3481	AGGAATTAGAGGACACACTTCAGGTTAGGCACATACAAGAGTTGAGAAGGTTATGACAG	3540
Qy	3550	ACCACAGAGTTCTTGAGGAATTAAAAAGAAAATCAACAAATAATTAAATCAAATAC	3609
Db	3541	ACCACAGAGTTCTTGAGGAATTAAAAAGAAAACCAACAAATAATTAAATCAAATAC	3600
Qy	3610	AAGAATCTCATGCTGAAATTATCCAGGAAAAAGAAAAACAGTTACAGGAATTAAACTCA	3669
Db	3601	AAGAATCTCATGCTGAAATTATCCAGGAAAAAGAAAAACAGTTACAGGAATTAAACTCA	3660
Qy	3670	AGGTTCTGATTGTCAGACACGAGATGCAAGTTAGAGGTTGAATTGCGTTGAAGGAAG	3729
Db	3661	AGGTTCTGATTGTCAGACACGAGATGCAAGTTAGAGGTTGAATTGCGTTGAAGGAAG	3720
Qy	3730	CAGAAACTGATGAAATAAAATTGCTGGAAGAAAGCAGAGCCCAGCAGAAGGAGACCT	3789
Db	3721	CAGAAACTGATGAAATAAAATTGCTGGAAGAAAGCAGAGCCCAGCAGAAGGAGACCT	3780
Qy	3790	TGAAATCTCTCTGAAACAAGAGACAGAAAATTGAGAACAGAAATTGAAACTCAACC	3849
Db	3781	TGAAATCTCTCTGAAACAAGAGACAGAAAATTGAGAACAGAAATTGAAACTCAACC	3840
Qy	3850	AAAAGATTCAAGGATAATAATGAAAATTATCAGGTGGGCTTAGCAGAGCTAAGAACTTAA	3909
Db	3841	AAAAGATTCAAGGATAATAATGAAAATTATCAGGTGGGCTTAGCAGAGCTAAGAACTTAA	3900
Qy	3910	TGACAATTGAAAAAGATCAGCGTATTCCGAGTTAATTGAGACATGAAGAAGAATCTA	3969
Db	3901	TGACAATTGAAAAAGATCAGTGATTCCGAGTTAATTGAGACATGAAGAAGAATCTA	3960

Art Unit: 1642

Qy 3970 ATATACTTAAAGCTGAATTAAACAAAGTAACATCTTGATAACCAAGCATTGAAATAG 4029
|||
Db 3961 ATATACTTAAAGCTGAATTAAACAAAGTAACATCTTGATAACCAAGCATTGAAATAG 4020

Qy 4030 AAAAAAACCTAAAAGAACAAATAATTGAACCTGCAGAGTAAATTGGATTAGAATTGAGTG 4089
|||
Db 4021 AAAAAAACCTAAAAGAACAAATAATTGAACCTGCAGAGTAAATTGGATTAGAATTGAGTG 4080

Qy 4090 CTCTGAAAGACAAAAAGATGAAAAAATTACCAACAAGAACAGAGAAATACGAAGCTATTA 4149
|||
Db 4081 CTCTGAAAGACAAAAAGATGAAAAAATTACCAACAAGAACAGAGAAATACGAAGCTATTA 4140

Qy 4150 TCCAGAACCTTGAGAAAGACAGACAAAAATTGGTCAGCAGCCAGGAGCAAGACAGAGAAC 4209
|||
Db 4141 TCCAGAACCTTGAGAAAGACAGACAAAAATTGGTCAGCAGCCAGGAGCAAGACAGAGAAC 4200

Qy 4210 AGTTAATTCAAGCTTAATTGTGAAAAAGATGAAGCTATTCAAGACTGCCCTAAAAGAAT 4269
|||
Db 4201 AGTTAATTCAAGCTTAATTGTGAAAAAGATGAAGCTATTCAAGACTGCCCTAAAAGAAT 4260

Qy 4270 TTAAATTGGAGAGAGAAGTTGAGAAAGAGTTATTAGAAAAGTTAACATCTTGAGA 4329
|||
Db 4261 TTAAATTGGAGAGAGAAGTTGAGAAAGAGTTATTAGAAAAGTTAACATCTTGAGA 4320

Qy 4330 ATCAAATAGCAAAAGTCCGCCATTGACTCTACAGAGGGATTCTCAAGCTTAGTTG 4389
|||
Db 4321 ATCAAATAGCAAAAGTCCGCCATTGACTCTACAGAGGGATTCTCAAGCTTAGTTG 4380

Qy 4390 CTGAACCTCAAGAAAAGCTTCAGGAAGAAAAGCTAAGTTCTAGAACAACTGAAGAGC 4449
|||
Db 4381 CTGAACCTCAAGAAAAGCTTCAGGAAGAAAAGCTAAGTTCTAGAACAACTGAAGAGC 4440

Qy 4450 AAGAAAAAAGAAGAATGAAGAAATGCAAAATGTTCAACATCTTGATTGCGAACAC 4509
|||
Db 4441 AAGAAAAAAGAAGAATGAAGAAATGCAAAATGTTCAACATCTTGATTGCGAACAC 4500

Qy 4510 AGACCAATTAAACACTGTTAACAGAGAGAAAATGAGAAAAGAAAACATAATAATG 4569
|||
Db 4501 AGACCAATTAAACACTGTTAACAGAGAGAAAATGAGAAAAGAAAACATAATAATG 4560

Qy 4570 ATCTTAGTGATAAGTTGAAAAGTACAATGCAGCAACAAGAACGGATAAAGATTGATAG 4629
|||
Db 4561 ATCTTAGTGATAAGTTGAAAAGTACAATGCAGCAACAAGAACGGATAAAGATTGATAG 4620

Qy 4630 AGTCACCTTCTGAAGATCGAGCTCGTTGCTTGAGAAAAGAAAAGCTTGAAGAAG 4689
|||
Db 4621 AGTCACCTTCTGAAGATCGAGCTCGTTGCTTGAGAAAAGAAAAGCTTGAAGAAG 4680

Qy 4690 TCAGTAAGTTGCGCAGTAGCAGTTGTTCCCTCACCATATGTAGCTACAGCCCCAGAAC 4749
|||
Db 4681 TCAGTAAGTTGCGCAGTAGCAGTTGTTCCCTCACCATATGTAGCTACAGCCCCAGAAC 4740

Qy 4750 TTTATGGAGCTGTGCACCTGAACCTCCCAGGTGAATCAGATAGATCCGCTGTGGAAACAG 4809
|||
Db 4741 TTTATGGAGCTGTGCACCTGAACCTCCCAGGTGAATCAGATAGATCCGCTGTGGAAACAG 4800

Qy 4810 CAGATGAAGGAAGAGTGGATTCAAGCAATGGAGAACAGCATGATGTCTGTACAAGAAAATA 4869
|||
Db 4801 CAGATGAAGGAAGAGTGGATTCAAGCAATGGAGAACAGCATGATGTCTGTACAAGAAAATA 4860

Qy 4870 TTCATATGTTGCTGAAGAAAAACAGCGGATAATGCTGTTAGAACGAACATTGCAATTGA 4929
|||
Db 4861 TTCATATGTTGCTGAAGAAAAACAGCGGATAATGCTGTTAGAACGAACATTGCAATTGA 4920

Qy 4930 AAGAAGAAGAAAATAACGGTTAATCAAAGACTGATGTCTCAGAGCATGTCTCAGTAT 4989
|||

Art Unit: 1642

Db	4921	AAGAAGAAGAAAATAACGGTAAATCAAAGACTGATGTCAGAGCATGCTTCAGTAT	4980
Qy	4990	CTTCAAGGCATTCTGAAAAGATAGCTATTAGAGATTTCAGGTGGAGATTGGTACTCA	5049
Db	4981	CTTCAAGGCATTCTGAAAAGATAGCTATTAGAGATTTCAGGTGGAGATTGGTACTCA	5040
Qy	5050	TCATCCTAGACGAACGCCATGACAATTATGTGTTATTACTGTTAGTCCTACTTATATT	5109
Db	5041	TCATCCTAGACGAACGCCATGACAATTATGTGTTATTACTGTTAGTCCTACTTATATT	5100
Qy	5110	TTCTACATTCAAGAGTCTCACCGCCCTGGATCTAAACCAGGTGAGGGTGCTTCAGGTG	5169
Db	5101	TTCTACATTCAAGAGTCTCACCGCCCTGGATCTAAACCA-----GCTTCAGGTG	5151
Qy	5170	CATCTAGAAGACCTGGTACTGGAAAAGTAATGGAAAAAGAATACTGTCAGCCAAA	5229
Db	5152	CATCTAGAAGACCTGGTACTGGAAAAGTAATGGAAAAAGAATACTGTCAGCCAAA	5211
Qy	5230	AGGCACAAAACAGATTAAAGTCCTTGGGACAAAGTTTACAGAGTGAAGCCGTAT	5289
Db	5212	AGGCACAAAACAGATTAAAGTCCTTGGGACAAAGTTTACAGAGTGAAGCCGTAT	5271
Qy	5290	CATGGAATAAGAAAGTATAACTTATGGACAAAATTACATTCTATGACATTTCCT	5349
Db	5272	CATGGAATAAGAAAGTATAACTTATGGACAAAATTACATTCTATGACATTTCCT	5331
Qy	5350	GATTTGTCCTGCAGTGCTCATTCACTCCAAAACAGCAGGCCATCTTTATGCAA	5409
Db	5332	GATTTGTCCTGCAGTGCTCATTCACTCCAAAACAGCAGGCCATCTTTATGCAA	5391
Qy	5410	AGTCAGCGTGACAATATACTTCACTGGTGTACCGTTACTTTTAACTGGCTTCATT	5469
Db	5392	AGTCAGCGTGACAATATACTTCACTGGTGTACCGTTACTTTTAACTGGCTTCATT	5451
Qy	5470	TAGGAATAATAATTACATCAGAACCTGGCTGAATTAAATGGTTTTGGTT	5529
Db	5452	TAGGAATAATAATTACATCAGAACCTGGCTGAATTAAATGGTTTTGGTT	5511
Qy	5530	TTTTTTTACCCAGACAACCTAGAAATGCGGACCAACTACTTCATTCTCAAAGGG	5589
Db	5512	TTTTTTTACCCAGACAACCTAGAAATGCGGACCAACTACTTCATTCTCAAAGGG	5571
Qy	5590	CATACCTTGTGCATTGGCTTATGATGAGCCATTAAATTGCTGTTAAATACACTA	5649
Db	5572	CATACCTTGTGCATTGGCTTATGATGAGCCATTAAATTGCTGTTAAATACACTA	5631
Qy	5650	GCTTGAACCTAGATGTTAAATGTTATTACCAAGCATTGCTTTGTGAAATCAGTA	5709
Db	5632	GCTTGAACCTAGATGTTAAATGTTATTACCAAGCATTGCTTTGTGAAATCAGTA	5691
Qy	5710	TCAGAACATTGCACTTTAACACATTCTTATAAAATGTATAATTTCAGAACTAT	5769
Db	5692	TCAGAACATTGCACTTTAACACATTCTTATAAAATGTATAATTTCAGAACTAT	5751
Qy	5770	TTAAAATAAGAGGAGTGTATTGATGCTGATAATCATTGAGTTGCCTCAGTAGAT	5829
Db	5752	TTAAAATAAGAGGAGTGTATTGATGCTGATAATCATTGAGTTGCCTCAGTAGAT	5811
Qy	5830	ACTAAAGCAAATTGTTCACTGGTATTGATGTTCAAAAAAAAGGA	5889
Db	5812	ACTAAAGCAAATTGTTCACTGGTATTGATGTTCAAAAAAAAGGA	5871
Qy	5890	ACTGTAATTGATTGACTGATTTAAGATCAGCCATAAGTAATCAGCAATCTCAAAGC	5949
Db	5872	ACTGTAATTGATTGACTGATTTAAGATCAGCCATAAGTAATCAGCAATCTCAAAGC	5931
Qy	5950	ACTTTCAGTGGATTGGTCATCTGGTTCTAAAGGGAAGAGTCTGTGCTACTAACCATTC	6009

Art Unit: 1642

LOCUS **D86958** **6614 bp** **mRNA** **linear** **PRI** **22-AUG-1996**
DEFINITION Human male myeloblast mRNA for KIAA0203 protein, complete cds.
ACCESSION D86958
VERSION D86958 GI:1503989
KEYWORDS KIAA0203 protein.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 6614)
AUTHORS Nomura,N.
TITLE Direct Submission
JOURNAL Submitted (02-AUG-1996) Nobuo Nomura, Kazusa DNA Research
Institute; 1532-3 Yanauchino, Kisarazu, Chiba 292, Japan
(E-mail:cdnainfo@kazusa.or.jp, Tel:0483-52-3930, Fax:0483-52-3931)
REFERENCE 2 (bases 1 to 6614)
AUTHORS Nagase,T., Seki,N., Ishikawa,K., Ohara,O. and Nomura,N.
TITLE Prediction of the coding sequences of unidentified human genes. VI.
The coding sequences of 80 new genes (KIAA 0201 - KIAA 0280)

Art Unit: 1642

deduced by analysis of cDNA clones from human cell line KG-1 and brain

JOURNAL Unpublished (1996)

FEATURES Location/Qualifiers

source 1..6614

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon: 9606"

/chromosome="8"

/sex="male"

/cell_line="KG-1"

/cell_type="myeloblast"

5' UTR

gene 1..515

516..5291

/gene="KIAA0203"

CDS 516..5291

/gene="KIAA0203"

/note="The KIAA0203 protein has similarity to mouse CC1."

/citation=[2]

/codon_start=1

/product="KIAA0203 protein"

/protein_id="1503990"

/db_xref="GI:1503990"

/translation="MKLYVFLVNTGTTLFDTELTVTQTVADLKHAIQSKYKIAIQHQV
 LVVNGCEMAADRVCYTSAGTDNPIFLFNKEMILCDRPPAIPKTTFSTENDMEIKV
 EESLMMMPAVFHTVASRQLALEMYEVAKKLCSCFCEGLVHDEHLHQGWAAIMANLED
 SNSYQKLLFKFESIYSNYLQSIEDIKLKLTHLGTAVSVMAKIPIPCLTRHSYRECLG
 RLDSLPEHEDSEKAETKRSTELVLSMPMPRTTNESSLTSFPKSVEHVSPTADAESGK
 EIRESCQSTVHQQDETTIDTKDGLLEFFNVSLLDWINVQDRPNDVESLVRKCFDSMSR
 LDPPRIIRPFIACRQTIAKLDNQNMQKAIKGLEDRLYALDQMIAASCGRLVNEQKELAQG
 FLANQKRAENLKDASVLPDLCLSHANQMLIMQLQNHRKLLDIQKCTTAKQELANNLHV
 RLKWCFCVMLHADQDGKQLQALLRLVIELLERVKIVEALSTVPQMYCLAVVEVRRKM
 FIKHYREWAGALVKDGKRLYEAEKSKRESFGKLFRKSFRLRNRLFRGLDSWPSFCTQK
 PRKFDCELPDISLKDLDLQFLQSFCPSEVQPFLRVPLLCDFEPLHQHVIALHNLVKAQS
 LDEMSQTITDLSSEQKASVQSPQASSPRMESTAGTTTSPRTPPPLTVQDPLCP
 AVCLEELSPDSIDAHTFDFETIPHPNIEQTIHQVQLLDSLAEESPESDFMSAVNEFV
 IEEENLSSPNPISDPQSPMEMMVESLYSSVINAIDSRRMQDNTVCGKEDFGDHTSLNQL
 ERCRVVAQDSHFSIQTICKEDLCHFRTVQKEQCDFSNSLKCTAVEIRNIEKVKCSLE
 ITLKEKHQKELLSLKNEYEGKLDGLIKEENENIKKLKGELVCLEEVLQNKDNEFA
 LVKHEKEAVICLQNEKDQLLEMENTIMHSQNCEIKELKQSREIVLEDLKKLHVENDEK
 LQLLRAELQSLEQSHLKELEDTLQVRHIQFEKVMTDHRSLEELKKENQQIINQIQE
 SHAEI IQEKEKQLQBLKLKVSDLSDTRCKLEVELALKEAETDEIKILLEESRAQQKET
 LKSLLEQETENLRTEISKLNQKIQDNNEVYQVGLAELRTLMTIEKDQCISELISRHEE
 ESNILKAELNKVTSLHNQAFEIEKNLKEQIIIELQSKLDSELSALERQKDEKITQQEEK
 YEATIQNLEKDRQKLVSQEQDREQLIQQLNCEKDEAIQTALKFKEREVVEKELLE
 KVKHLENQIAKSPAIDSTRGDSSSLVAELQEKLQEEAKFLEQLEEQEKRKNEEMQNV
 RTSLIAEQQTNFNTVLTREKMRKENITNDLSDKLKSTMQQQERDKDLIESLSEDRARL
 LEEKKKLEEVEVSKLRSFFVPSPYVATAPELYGACAPELPGESDRSAVETADEGRVDS
 AMETSMSMSVQENIHMSEEKQRIMLLERTLQLKEEENKRLNQRLMSQSMSSVSSRHSE
 KIAIRDFQVGDLVLIILDERHDNYVFTVSPPLYFLHSESLPALDKPASGASRRPWV
 LGKVMKEYCQAKKAQNRFKVPLGKFYRVKAVSWNKKV"

3' UTR

5292..6614

ORIGIN

1 aacaaaccacaa gccggggccgg tggccggcgc cctggccgac cctccggcgtt gcctcagaat
 61 ccccccagtcg cctggggcccc tggctctga caggccggcc cttctgtcc ccggggccca
 121 gaccaggagc cgagggggcct gtcgcgtcc ttgtccggcc ggacccctcc ctgcctcc
 181 gagttccgggg ccgcgggggg cgggcggcccg ggacccggc ggttgtgtcg gcttagcggt
 241 gccgaatggg cggttggtaa ccgcgtccgcg ggaatggcgc gccggggaaag atggccgg
 301 gggtcgtcgg ctctgtgtc gccggccggc aaggaggagg cgtggccggg tttctgagtt
 361 taaccatggaa tgccattcag ttgccaatct caagccaaagc aaacataagc cagttttat
 421 ctactttta agaaaatgg tagtccttt cacatgcct gacgttaactg tatcagagg
 481 tgaggatataa gctcacagaa ttccatggaa tcacatggaa gtttatatgtt tttctggta
 541 acactggAAC tactctaaca ttgcacactg aacttacagt gcaaactgtg gcagaccta
 601 agcatgcat tcaaaagccaa tacaagattt ctatcaaca ccagggtctg gtgtcaatg
 661 gaggagaatg catggctgca gatggaaatgg tggtaatctt cagttgtgggg acggataacaa
 721 atccaaatttt tctttttaaatggaaatgg tctttatgtt cttgtccacatc gctatccat
 781 aaactacccctt ttccatggaa atggatggaa aaataaaaatgg tggaaatgtt ctatgtac

Art Unit: 1642

841 ctgcagttt tcatactgtt gcttcaagga cacagttgc attggaaatg tatgaagtg
901 ccaagaaact ttgttcttt tggtaaggc ttgtacatga tgaacatctt caacaccaag
961 gctgggctgc aatcatggcc aacctggagg actgttcaaa ttcataccaa aagctacttt
1021 tcaagttga aagtatttat tcaaaatttac tgcagttccat agaagacatc aagttaaaac
1081 ttactcattt aggaactgca gtttcaagat tccactgtt gatgtcctaa
1141 ccagacatag ttacagagaa tggggaa gactggatc ttacactgaa catgaagact
1201 cagaaaaaagc tgagacgaaa agatccactg aactggtgc ctctctgtat atgcotagaa
1261 caactaacga atcttgcgta acctcattt ccaagtcgt ggaacatgtg tccccagata
1321 cccgagatgc tggaaatgtt gggaaatctt tcaaaatgtt gttcatcagc
1381 aagatggaaac tacgattgac actaaatgtt gtatctgc cttttttat gtctctttgt
1441 tagactggat aaatgttcaaa tggaaatgtt atgttgcgaa atcttggtc aggaagtgt
1501 ttgattctat gggccatggc gatccaaatggc ttatccgacc atttatacgaa qaatggcgtc
1561 aaactattgc caaacttgcgaa aatcagaata tggaaatgtt gaaaggactt gaagatcgcc
1621 tctacggcctt ggaccagatg attgtatgtt gtggccgact ggtgaatgaa cagaaagagc
1681 ttgtcaggg attttatgtt aatcagaata gggccatggc cttttttat gtctctttgt
1741 tacgtgattt atgcctgtt caccgcatac agtgcgttgc atgttgcgaa aatcatagaa
1801 aactgttgcgaa tggaaatgtt gggccatggc aatcagaata aataacccat
1861 atgtcagatgc gggccatggc tggccatggc tggccatggc tggccatggc ggagagaatg
1921 tacaagctttt gctccgcctt gtaatagatc tggccatggc tggccatggc tggccatggc
1981 ttagtacatgc tccctcgatgc tggccatggc tggccatggc tggccatggc tggccatggc
2041 tcataaaaaca ctacaggggatggcc tggccatggc tggccatggc tggccatggc tggccatggc
2101 aagcagaaaaa atcaaaaagg gatccatggcc tggccatggc tggccatggc tggccatggc
2161 atcgctctttt tagggactt gactccgtt ccccttcctt tggccatggc tggccatggc
2221 agtttgcgtt tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
2281 gtccttcggatggcc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
2341 accagcatgtt acttgcgttgc cataatttggcc tggccatggc tggccatggc tggccatggc
2401 cacagaccat tacagatctt tggccatggc tggccatggc tggccatggc tggccatggc
2461 agtctgcctt ttcaccatggcc tggccatggc tggccatggc tggccatggc tggccatggc
2521 gaactccctcc accactgtt gttccatggc tggccatggc tggccatggc tggccatggc
2581 aattatctcc accactgtt gttccatggc tggccatggc tggccatggc tggccatggc
2641 acatagaaca gacttttgc tggccatggc tggccatggc tggccatggc tggccatggc
2701 aatcgttgcgaa tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
2761 atccctataag tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
2821 tcaatgcgtt gggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
2881 gagatcatac ttttgcgtt gggccatggc tggccatggc tggccatggc tggccatggc
2941 acttcgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3001 aacagtgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3061 aaaaatgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3121 ctttttttttt tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3181 aaaaatgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3241 aagataatgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3301 aaaaatgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3361 aagaactgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3421 atgttgcgtt gggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3481 aggaaatgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3541 accacacgtt gggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3601 aagaatcttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3661 agtttgcgtt gggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3721 cagaactgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3781 tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3841 aaaaatgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3901 tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
3961 atatactttttt tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4021 aaaaatgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4081 ctgttgcgtt gggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4141 tccatgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4201 agtttgcgtt gggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4261 tttttttttt tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4321 atcaatgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4381 ctgttgcgtt gggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4441 aaaaatgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4501 agaccaatttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4561 atttttttttt tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4621 agtctgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4681 tttttttttt tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4741 tttttttttt tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc
4801 cagatgttgc tggccatggc tggccatggc tggccatggc tggccatggc tggccatggc

Art Unit: 1642

11

 NCBI

Blast 2 Sequences results

[PubMed](#)
[Entrez](#)
[BLAST](#)
[OMIM](#)
[Taxonomy](#)
[Structure](#)

BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.18 [Mar-02-2008]

Matrix: BLOSUM62
gap open: 11
gap extension: 1

x_dropoff: 0
expect: 300.0
wordsize: 3
Filter
View option
Standard

Masking character option
X for protein, n for nucleotide
Masking color option


Black

Show CDS translation
Align


Sequence 1: gi|40788906|KIAA0203 [Homo sapiens]
Length = 1593 (1 .. 1593)

Sequence 2: gi|119607126|RB1-inducible coiled-coil 1, isoform CRA_b [Homo sapiens]
>gi|168272926|dbj|BAG10302.1| RB1-inducible coiled-coil protein 1 [synthetic construct]

Length = 1591 (1 .. 1591)



NOTE: Bitscore and expect value are calculated based on the size of the nr database.



Score = 3112 bits (8067), Expect = 0.0
 Identities = 1591/1591 (100%), Positives = 1591/1591 (100%), Gaps = 0/1591 (0%)

Query 3	MKLYVFLVNTGTTLTFDTTELTVQTVADLKHAIQSKYKIAIQHQVLVNGGECMAADRRVC	62
Sbjct 1	MKLYVFLVNTGTTLTFDTTELTVQTVADLKHAIQSKYKIAIQHQVLVNGGECMAADRRVC	60
Query 63	TYSAGTDTNPIFLNKEMILCDRPPAIPKTTFSTENDMEIKVEESLMMPAVFHTVASRTQ	122
Sbjct 61	TYSAGTDTNPIFLNKEMILCDRPPAIPKTTFSTENDMEIKVEESLMMPAVFHTVASRTQ	120
Query 123	LALEMYEVAKKLCSFCEGLVHDEHLQHQGWAAIMANLEDCSNSYQKLLFKFESIYSNYLQ	182
Sbjct 121	LALEMYEVAKKLCSFCEGLVHDEHLQHQGWAAIMANLEDCSNSYQKLLFKFESIYSNYLQ	180
Query 183	SIEDIKLKLTHLGTAVSVMAKIPPLECLTRHSYRECLGRRLDSLPEHEDSEKAETKRSTEL	242
Sbjct 181	SIEDIKLKLTHLGTAVSVMAKIPPLECLTRHSYRECLGRRLDSLPEHEDSEKAETKRSTEL	240
Query 243	VLSPDMPRTTNESLLTSFPKSVEHSPDTADAESGKEIRESCQSTVHQDETTIDTKGD	302
Sbjct 241	VLSPDMPRTTNESLLTSFPKSVEHSPDTADAESGKEIRESCQSTVHQDETTIDTKGD	300
Query 303	LPFFNVSLLDWINVQDRPNDVESLVRKCFDSMSRLDPRIIRPFIAECRQTIAKLDNQNMK	362
Sbjct 301	LPFFNVSLLDWINVQDRPNDVESLVRKCFDSMSRLDPRIIRPFIAECRQTIAKLDNQNMK	360
Query 363	AIKGLEDRLYALDQMIASCGRLVNEQKELAQGFLANQKRAENLKDASVLPDLCLSHANQL	422
Sbjct 361	AIKGLEDRLYALDQMIASCGRLVNEQKELAQGFLANQKRAENLKDASVLPDLCLSHANQL	420
Query 423	MIMLQNHRKLLDIKQKCTTAKQELANNLHVRLKWCCFVMLHADQDGEKLQALLRLVIELL	482
Sbjct 421	MIMLQNHRKLLDIKQKCTTAKQELANNLHVRLKWCCFVMLHADQDGEKLQALLRLVIELL	480
Query 483	ERVKIVEALSTVPQMYCLAVVEVVRKMFIFKHYREWAGALVKDGKRLYEAESKRESFGK	542
Sbjct 481	ERVKIVEALSTVPQMYCLAVVEVVRKMFIFKHYREWAGALVKDGKRLYEAESKRESFGK	540
Query 543	LFRKSFLRNRLFRGLDSWPPSFCTQKPRKFDCELPDISLKDQFLQSFCPSEVQPFLRP	602

Art Unit: 1642

Sbjct	541	LFRKSFLRNRLFRGLDSWPPSFCTQKPRKFDCELPDISLKDLQFLQSFPCSEVQPFLRVP	600
Query	603	LLCDFEPLHQHVVLALHNLVKAAQSLDEMSQTIDLLSEQKASVSQTSPQSASSPRMESTA	662
Sbjct	601	LLCDFEPLHQHVVLALHNLVKAAQSLDEMSQTIDLLSEQKASVSQTSPQSASSPRMESTA	660
Query	663	GTTTTSPPRTPPLTVQDPLCPAVCPLCPEELSPDSIDAHTDFETIPHNPIEQTIHQVSLD	722
Sbjct	661	GTTTTSPPRTPPLTVQDPLCPAVCPLCPEELSPDSIDAHTDFETIPHNPIEQTIHQVSLD	720
Query	723	LDLSAESPESDFMSAVNEFVIEENLSSPNPISDPQSPEMMVESLYSSVINAIDSRRMQDT	782
Sbjct	721	LDLSAESPESDFMSAVNEFVIEENLSSPNPISDPQSPEMMVESLYSSVINAIDSRRMQDT	780
Query	783	NVCGKEDFGDHTSLNVQLERCRVVAQDSHFSIQTIKEDELCHFRTFVQKEQCDFSNSLKCT	842
Sbjct	781	NVCGKEDFGDHTSLNVQLERCRVVAQDSHFSIQTIKEDELCHFRTFVQKEQCDFSNSLKCT	840
Query	843	AVEIRNIEKVKCSLEITLKEHKQELLSLKNEYEGKLDGLIKETEENENKIKKLKGELV	902
Sbjct	841	AVEIRNIEKVKCSLEITLKEHKQELLSLKNEYEGKLDGLIKETEENENKIKKLKGELV	900
Query	903	CLEEVLQNQKDNEFALVKHEKEAVICLQNEKDQKLLEMENIMHSQNCEIKELKQSREIVLE	962
Sbjct	901	CLEEVLQNQKDNEFALVKHEKEAVICLQNEKDQKLLEMENIMHSQNCEIKELKQSREIVLE	960
Query	963	DLKKLHVENDEKLQLLRAELQSLEQSHLKELEDTLQVRHIQEFEKVMTDHRVSLEELKKE	1022
Sbjct	961	DLKKLHVENDEKLQLLRAELQSLEQSHLKELEDTLQVRHIQEFEKVMTDHRVSLEELKKE	1020
Query	1023	NQQIINQIQESHAIIQEKEKQLQELKLKVSDSLSDTRCKLEVELALKEAETDEIKILLE	1082
Sbjct	1021	NQQIINQIQESHAIIQEKEKQLQELKLKVSDSLSDTRCKLEVELALKEAETDEIKILLE	1080
Query	1083	SRAQQKETLKSLLQETENLRTEISKLNQKIQDNNENYQVGLAELRTLMTIEKDQCISEL	1142
Sbjct	1081	SRAQQKETLKSLLQETENLRTEISKLNQKIQDNNENYQVGLAELRTLMTIEKDQCISEL	1140
Query	1143	ISRHEEESNLKELNKVTSLHNQAFEIEKNLKEQIIELQSKLDSELSALERQKDEKITQ	1202
Sbjct	1141	ISRHEEESNLKELNKVTSLHNQAFEIEKNLKEQIIELQSKLDSELSALERQKDEKITQ	1200
Query	1203	QEEKYEAIIQNLKDRQKLVSSQEQDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKEL	1262
Sbjct	1201	QEEKYEAIIQNLKDRQKLVSSQEQDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKEL	1260
Query	1263	LEVKVHLENQIAKSPAIDSTRGDSSLVAELQEKLQEEKAKFLEQLEEQEKRKNEEMQNV	1322
Sbjct	1261	LEVKVHLENQIAKSPAIDSTRGDSSLVAELQEKLQEEKAKFLEQLEEQEKRKNEEMQNV	1320
Query	1323	RTSLIAEQQTNTVLTREKMRKENIINDLSDKLSTMQQQERDKDLIESLSEDRAARLLE	1382
Sbjct	1321	RTSLIAEQQTNTVLTREKMRKENIINDLSDKLSTMQQQERDKDLIESLSEDRAARLLE	1380
Query	1383	EKKKLEEEVSKLRSSSFVPSPYVATAPELYGACAPELPGESDRSAVETADEGRVDSAMET	1442
Sbjct	1381	EKKKLEEEVSKLRSSSFVPSPYVATAPELYGACAPELPGESDRSAVETADEGRVDSAMET	1440
Query	1443	SMMSVQENIHMLSEEKQRMILLERTLQLKEEENKRLNQRLMSQSMSSVSSRHSEKIAIRD	1502
Sbjct	1441	SMMSVQENIHMLSEEKQRMILLERTLQLKEEENKRLNQRLMSQSMSSVSSRHSEKIAIRD	1500
Query	1503	FQVGDLVLIILDERHDNYVLFTVSPTLYFLHSESLPALDLKPASGASRRPWLGVMEKE	1562
Sbjct	1501	FQVGDLVLIILDERHDNYVLFTVSPTLYFLHSESLPALDLKPASGASRRPWLGVMEKE	1560

Art Unit: 1642

Query 1563 YCQAKKAQNRFKVPLGTFYRVKAVSWNKKV 1593
YCQAKKAQNRFKVPLGTFYRVKAVSWNKKV
Sbjct 1561 YCQAKKAQNRFKVPLGTFYRVKAVSWNKKV 1591

CPU time: 0.04 user secs. 0.03 sys. secs 0.07 total secs.